Last reviewed · How we verify
NCT04686747: COVID - AGICT
COVID - 19 and Advanced Gastro-intestinal Cancer Treatment
trial in Pancreatic Cancer in 2,000 participants. Completed in 30 June 2021.
1 March 2021
Quick facts
| Lead sponsor | S.M. Misericordia Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 January 2021 |
| Primary completion | 1 March 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across Italy |
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Gastric Cancer — all drugs for Gastric Cancer →
- Esophagus Cancer — all drugs for Esophagus Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
S.M. Misericordia Hospital
Who can join
Adults 18 to 85, any sex, with Pancreatic Cancer or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a consequence of COVID-19?
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The COVID - AGICT study: COVID-19 and advanced gastro-intestinal cancer surgical treatment. A multicentric Italian study on the SARS-CoV-2 pandemic impact on gastro-intestinal cancers surgical treatment during the 2020. Analysis of perioperative and short-term oncological outcome
Giuliani G, Guerra F, Messinese S, Santelli F, et al · · 2023 · cited 5× · PMID 36924550 · DOI 10.1016/j.suronc.2023.101907 -
The MIS-COVID-AGICT Study: Trend of Minimally Invasive Surgery for Gastrointestinal Cancer Treatment During the First Waves of the COVID-19 Pandemic in Italy. Subgroup Analysis from the COVID-AGICT Study: COVID-19 and Advanced Gastrointestinal Cancer Surgical Treatment.
Giuliani G, Coletta D, Guerra F, Esposito S, et al · · 2023 · cited 1× · PMID 37130329 · DOI 10.1089/lap.2023.0058
Verify or expand the search:
- PubMed search for NCT04686747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other S.M. Misericordia Hospital trials
Trials by the same sponsor.
- NCT05829343 — RObotic Versus LAparoscopic Colectomy for DIverticulitis. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04686747 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by S.M. Misericordia Hospital
- Last refreshed: 3 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04686747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing